Author: heloadmin1

Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for which has now been accepted by the Food and Drug Administration In preclinical studies, administration of the dual-action CAR T cells followed by administration of […]

Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk of CMV events in high-risk transplant recipients Encouraging pilot study results demonstrate the benefit of vaccinating donors with Triplex to convey protective CMV-specific T cell immunity to allogeneic hematopoietic […]

Results demonstrate the potential benefit of vaccinating donors with Triplex to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transplant Helocyte, Inc., a subsidiary company of Fortress Biotech, is developing Triplex for the treatment of CMV Miami, FL – February 16, 2023 – Helocyte, Inc., (“Helocyte”) a subsidiary company […]

Phase 2 clinical trial planned to evaluate efficacy of Triplex-vaccinated donors to enhance protective CMV-specific T cell immunity in stem cell transplant recipients Helocyte, Inc., a subsidiary company of Fortress Biotech, is developing Triplex for the treatment of CMV Miami, FL – February 15, 2023 – Helocyte, Inc., (“Helocyte”) a subsidiary company of Fortress Biotech, […]

View PDF Miami, FL – August 11, 2022 – Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Triplex, a cytomegalovirus (“CMV”) vaccine being developed by its subsidiary Helocyte, Inc. (“Helocyte”), received a grant from the […]

Helocyte, Inc., a partner company of Fortress Biotech, is developing Triplex for the treatment of cytomegalovirus Clinical trial will evaluate whether Triplex, which was developed by City of Hope, is safe and effective in eliciting a CMV-specific immune response in people living with HIV and is thus able to reduce CMV replication New York, NY […]